Cargando…
Safety and Efficacy of an Immune Cell-Specific Chimeric Promoter in Regulating Anti-PD-1 Antibody Expression in CAR T Cells
T cells modified to co-express cytokine or other factors with chimeric antigen receptor (CAR) can induce substantial and persistent increases in antitumor capacity in vivo. However, the uncontrolled expression of cytokines or factors can lead to the overactivation of immune cells, causing severe adv...
Autores principales: | Fang, Yuan, Zhang, Yajun, Guo, Chuanxin, Chen, Chumeng, Gao, Haixia, Zhou, Xiumei, Liu, Tao, Qian, Qijun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490636/ https://www.ncbi.nlm.nih.gov/pubmed/32995356 http://dx.doi.org/10.1016/j.omtm.2020.08.008 |
Ejemplares similares
-
Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy
por: Zhang, Yajun, et al.
Publicado: (2021) -
Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility
por: Celichowski, Piotr, et al.
Publicado: (2023) -
Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer
por: Jin, Ke-Tao, et al.
Publicado: (2021) -
A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis
por: Ma, Qizhi, et al.
Publicado: (2022) -
Chimeric-Antigen-Receptor (CAR) T Cells and the Factors Influencing their Therapeutic Efficacy
por: Kravets, Victoria G, et al.
Publicado: (2017)